Radiology 2004, 231:491–499.PubMedCrossRef 17. Zielhuis SW, Nijsen JFW, De Roos R, Krijger GC, Van Rijk PP, Hennink WE, Van het Schip AD: Production of GMP-grade radioactive holmium loaded poly(l-lactic acid) microspheres for clinical application. Int J Pharm 2006, 311:69–74.PubMedCrossRef 18. Zielhuis SW, Nijsen JFW, Dorland L, Krijger GC, Van het

Schip AD, Hennink WE: Removal of chloroform from biodegradable therapeutic microspheres by radiolysis. click here Int J Pharm 2006, 315:67–74.PubMedCrossRef 19. Zielhuis SW, Nijsen JFW, Krijger GC, Van het Schip AD, Hennink WE: Holmium-loaded poly(L-lactic acid) microspheres: In vitro degradation study. Biomacromolecules 2006, 7:2217–2223.PubMedCrossRef 20. Nijsen JFW, Rook D, Brandt CJWM, Meijer R, Dullens H, Zonnenberg BA, De Klerk JMH, Van Rijk PP, Hennink WE, Van het Schip AD: Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. Eur J Nucl Med 2001, 28:743–749.PubMedCrossRef 21. Nijsen JFW: Radioactive holmium poly(L-lactic acid) microspheres for treatment of hepatic this website malignancies: efficacy in rabbits. PhD Thesis, Utrecht University, Tthe Netherlands find more 2001, 109–122. 22. Zielhuis SW, Nijsen JFW, Seppenwoolde JH, Bakker CJG, Krijger GC, Dullens HF, Zonnenberg BA, Van Rijk PP, Hennink WE, Van het Schip AD: Long-term toxicity

of holmium-loaded poly(L-lactic acid) microspheres in rats. Biomaterials 2007, 28:4591–4599.PubMedCrossRef Orotidine 5′-phosphate decarboxylase 23. Vente MAD, Nijsen JFW, De Wit TC, Seppenwoolde JH, Krijger GC, Seevinck PR, Huisman A, Zonnenberg BA, Van den Ingh TSGAM, Van het Schip AD: Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L: -lactic acid) microspheres in healthy pigs. Eur J Nucl Med Mol Imaging 2008, 35:1259–1271.PubMedCrossRef 24. Aaronson NK, Ahmedzai S, Berman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, De Haes JC, et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365–376.PubMedCrossRef

25. Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, Howell RW, Erdi AK, Aydogan B, Costes S, Watson EE, et al.: MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions–radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med 1999, 40:11S-36S.PubMed 26. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, et al.: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176–181.PubMedCrossRef 27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228–247.PubMedCrossRef 28.